Pharmaceutical News

RSS

New vaccine appears to be more effective in reducing 'bad' LDL cholesterol

A new cholesterol-lowering vaccine leads to reductions in 'bad' LDL cholesterol in mice and macaques, according to research published in Vaccine. The authors of the study, from the University of New Mexico and the National Institutes of health in the United States, say the vaccine has the potential to be a more powerful treatment than statins alone.

10 Nov 2015

L-DOPA drug may delay or prevent age-related macular degeneration

A drug already used safely to treat Parkinson's disease, restless leg syndrome and other movement disorders also could delay or prevent the most common cause of blindness affecting more than 9 million older Americans - age-related macular degeneration (AMD).

10 Nov 2015

Drug compounds target multiple pathways associated with myotonic dystrophy type 1

Efforts to treat myotonic dystrophy type 1, the most common form of muscular dystrophy, are in their infancy. In a new study, researchers report they have added new capabilities to an experimental drug agent that previously defeated only one of DM1's many modes of action. Their retooled compounds interrupt the disease's pathology in three ways.

10 Nov 2015

Drug used to treat Parkinson's and related diseases may delay or prevent macular degeneration

In a major scientific breakthrough, a drug used to treat Parkinson's and related diseases may be able to delay or prevent macular degeneration, the most common form of blindness among older Americans.

10 Nov 2015

Type 2 diabetes drug significantly reduces hospitalizations, death from heart failure

For the first time, research shows that a type 2 diabetes drug significantly reduces hospitalizations and death from heart failure.

10 Nov 2015

PAREXEL expands market access and clinical evidence services

PAREXEL International Corporation, a leading global biopharmaceutical services provider, today announced expanded evidence-based services for biopharmaceutical products.

10 Nov 2015

New review finds scant scientific evidence supporting use of cannabinoids in rheumatic diseases

Although there are anecdotal reports indicating that cannabinoids, especially marijuana (or herbal cannabis), may be of therapeutic benefit for some patients with rheumatic complaints, a new review published in Arthritis Care & Research, a journal of the American College of Rheumatology, finds scant scientific evidence supporting any use of cannabinoids in rheumatic diseases. Furthermore, not a single controlled study has examined herbal cannabis in the rheumatology patient population.

10 Nov 2015

European regulator concludes that evidence does not support a causal relationship between human papillomavirus vaccines and CRPS or POTS

The European Medicines Agency’s Pharmacovigilance Risk Assessment Committee (PRAC) has completed a detailed scientific review of the evidence surrounding reports of two syndromes, complex regional pain syndrome (CRPS) and postural orthostatic tachycardia syndrome (POTS) in young women given human papillomavirus (HPV) vaccines.

10 Nov 2015

Paratek initiates Omadacycline phase 3 clinical study in community acquired bacterial pneumonia (CABP)

Paratek Pharmaceuticals, Inc. has announced the dosing of the first patient in its Phase 3 clinical study of its lead drug candidate, omadacycline, for the treatment of Community Acquired Bacterial Pneumonia (CABP). This global Phase 3 study will assess the efficacy and safety of omadacycline compared with moxifloxacin in subjects with CABP.

9 Nov 2015

AACR rapid and dramatic responses in TRK fusion patients

Loxo Oncology, Inc., a biopharmaceutical company innovating the development of highly selective medicines for patients with genetically defined cancers, today announced new results from its Phase 1 open-label, dose-escalation trial of LOXO-101, a selective inhibitor of tropomyosin receptor kinase (TRK) signaling molecules, and the first preclinical data for its RET and FGFR programs. The data are being presented at the 2015 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics in Boston.

9 Nov 2015

Armaron Bio starts Phase 2 trial for novel lead candidate drug for heart failure

Armaron Bio, a Melbourne-based drug development company focused on heart failure and other diseases, is pleased to announce that it has begun its Phase II clinical trial for NP202, its novel lead candidate drug for heart failure.

9 Nov 2015

$Ixazomib’s phase 3 study in relapsed/refractory multiple myeloma presented$

Ixazomib’s phase 3 study in relapsed/refractory multiple myeloma presented

Takeda Pharmaceutical Company Limited today announced that it will present Phase 3 data from the TOURMALINE-MM1 ixazomib clinical trial at the 57th American Society of Hematology (ASH) Annual Meeting to be held in Orlando, Florida from December 5 to 8, 2015.

6 Nov 2015

New study compares effectiveness of clozapine with standard antipsychotics in adults with schizophrenia

In real-world settings, patients with schizophrenia whose symptoms do not respond to standard antipsychotic medications have better outcomes if they are switched to clozapine instead of another standard antipsychotic. They have fewer hospitalizations, stay on the new medication longer, and are less likely to need to use additional antipsychotics.

6 Nov 2015

MSU professor finds surprising results about drug use behaviors

Conducting an economic analysis of drug use is a particularly difficult endeavor, but for Michigan State University professor and economist Siddharth Chandra, it just meant taking a look at the history books.

6 Nov 2015

Genvoya approved as complete regimen for HIV treatment

The U.S. Food and Drug Administration today approved Genvoya (a fixed-dose combination tablet containing elvitegravir, cobicistat, emtricitabine, and tenofovir alafenamide) as a complete regimen for the treatment of HIV-1 infection in adults and pediatric patients 12 years of age and older.

6 Nov 2015

Majority of people not allergic to intravenous penicillins, say ACAAI allergists

Most people who think they're allergic to penicillin have been told so by a doctor after they've had a reaction to the drug. And the majority, even though they've never been allergy tested, never take penicillin again.

6 Nov 2015

Many seasonal allergy sufferers take OTC products rather prescription medications

Anyone suffering with seasonal allergies knows the local pharmacy carries shelves full of over-the-counter medications to help manage symptoms. Unfortunately, most seasonal allergy sufferers take over-the counter (OTC) products rather than the treatments they actually prefer - prescription medications.

5 Nov 2015

New research finds insufficient evidence for use of Omega 3 supplements in treating major depressive disorder

New research out today concludes that there is insufficient evidence for the use of taking an Omega 3 fatty acid supplement in treating major depressive disorder.

5 Nov 2015

GHIT Fund invests $10.7 million to fight malaria, TB, leishmaniasis and dengue

The Global Health Innovative Technology Fund, which in the last two years has invested US$43 million to develop innovative tools for fighting diseases worldwide, today announced it is investing $10.7 million at multiple points in the product development pipeline to seek new interventions for malaria, tuberculosis (TB), leishmaniasis and dengue.

5 Nov 2015

Estrogen-like drug may not be beneficial to women with Alzheimer's dementia

An estrogen-like drug, raloxifene, has no demonstrated benefit on memory and thinking skills for women with dementia due to Alzheimer's disease, according to a study published in the November 4, 2015, online issue of Neurology, the medical journal of the American Academy of Neurology.

5 Nov 2015

Pharmaceutical News

New vaccine appears to be more effective in reducing 'bad' LDL cholesterol

L-DOPA drug may delay or prevent age-related macular degeneration

Drug compounds target multiple pathways associated with myotonic dystrophy type 1

Drug used to treat Parkinson's and related diseases may delay or prevent macular degeneration

Type 2 diabetes drug significantly reduces hospitalizations, death from heart failure

PAREXEL expands market access and clinical evidence services

New review finds scant scientific evidence supporting use of cannabinoids in rheumatic diseases

European regulator concludes that evidence does not support a causal relationship between human papillomavirus vaccines and CRPS or POTS

Paratek initiates Omadacycline phase 3 clinical study in community acquired bacterial pneumonia (CABP)

AACR rapid and dramatic responses in TRK fusion patients

Armaron Bio starts Phase 2 trial for novel lead candidate drug for heart failure

Ixazomib’s phase 3 study in relapsed/refractory multiple myeloma presented

New study compares effectiveness of clozapine with standard antipsychotics in adults with schizophrenia

MSU professor finds surprising results about drug use behaviors

Genvoya approved as complete regimen for HIV treatment

Majority of people not allergic to intravenous penicillins, say ACAAI allergists

Many seasonal allergy sufferers take OTC products rather prescription medications

New research finds insufficient evidence for use of Omega 3 supplements in treating major depressive disorder

GHIT Fund invests $10.7 million to fight malaria, TB, leishmaniasis and dengue

Estrogen-like drug may not be beneficial to women with Alzheimer's dementia

Real-time Raman monitoring for pharmaceutical hot melt extrusion

Synthetic Psychedelics: A Growing Public Health Concern

How the Vutara VXL simplifies single-molecule imaging

Latest News